Anavex Life Sciences AVXL Stock Price Today

Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch. The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023. Anavex Life Sciences’ stock was trading at $9.26 at the start of the year. Since then, AVXL stock has decreased by 15.3% and is now trading at $7.84. Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat’s FREE daily newsletter.

There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

Anavex Life Sciences Releases Encouraging Long Term Data From Rett Syndrome Study

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum.

The biotech’s shares have been steadily leaking higher following positive late-stage Alzheimer’s disease trial results. Short-sellers have piled into this clinical-stage biopharma stock. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

• Upgrade to MarketBeat All Access to add more stocks to your watchlist.
• 3 Wall Street research analysts have issued 1 year target prices for Anavex Life Sciences’ shares.
• Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company.
• The consensus among Wall Street research analysts is that investors should “moderate buy” AVXL shares.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The company’s operating segment is into developing novel therapies for the management of CNS diseases.

The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. According to analysts, Anavex Life Sciences’s stock has a predicted upside of 363.98% based on their 12-month price targets. Analysts like Anavex Life Sciences more than other Medical companies.

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Anavex Life Sciences 5g penny stocks in india Corp.’s stock surged 7.1% in premarket trade Friday, after the biopharmaceutical company said its Alzheimer treatment was granted orphan drug designation by the Food and Drug Administration. Anavex Life Sciences Corp. shares rose 37.7% in morning trade Wednesday to $4.35 per share after the biotech said it signed an agreement with Biogen Inc. to test its lead drug candidate.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. IShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.

Zacks Mobile App

We’d like to share more about how we work and what drives our day-to-day business. Compare
AVXL’s historical performance
against its industry peers and the overall market. Shares of Anavex Life Sciences Corp. edged up 1% in morning trading after the biopharmaceutical company said its experimental mid-stage treatment for Alzheimer’s disease reported lower rates of cognitive decline.

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to https://1investing.in/ shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Investors are celebrating the asset sale agreement with heavy trading of AVTX stock.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of AVXL stock can currently be purchased for approximately $7.84. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.

Private Companies

There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “moderate buy” AVXL shares. According to the issued ratings of 3 analysts in the last year, the consensus rating for Anavex Life Sciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for AVXL. The average twelve-month price prediction for Anavex Life Sciences is $43.25 with a high price target of $80.00 and a low price target of $11.00. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. AVXL’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

• MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
• On average, they predict the company’s stock price to reach $43.25 in the next twelve months.
• As an investor, you want to buy stocks with the highest probability of success.

ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company was incorporated in 2004 and is headquartered in New York, New York. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s…

The consensus rating score for Anavex Life Sciences is 2.67 while the average consensus rating score for medical companies is 2.66. Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment. U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday.